MedTrace Logo

Safety and Immunogenicity of Pvs25-IMX313/Matrix-M1 Vaccine

NCT05270265 · Status: TERMINATED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2026-01-15

Study results available
· View outcomes & findings →

Summary

This is an open-label, single-centre, non-randomised, first-in-human Phase Ia study to assess the safety and immunogenicity of the Pvs25-IMX313 vaccine, administered in Matrix-M1 adjuvant.

Conditions

  • Malaria, Vivax

Interventions

BIOLOGICAL

Pvs25-IMX313/Matrix-M1

Three doses of Pvs25-IMX313 in Matrix-M1 at different concentrations

Sponsors & Collaborators

  • University of Oxford

    lead OTHER

Principal Investigators

  • Angela M Minassian, DPhil FRCP · Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, Oxford, United

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-02-09
Primary Completion
2023-07-31
Completion
2023-07-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05270265 on ClinicalTrials.gov